Sentences with phrase «cell lung tumors»

Not exact matches

Immune cells modified by CRISPR - Cas9 were inserted into a lung cancer patient at the West China Hospital in Chengdu in the hopes that they'll be able to fight tumors, and 10 people total will receive injections of CRISPR re-engineered cells in order to assess the method's safety.

However, the impact of the two methylation - regulating enzymes was still seen at 10 to 15 months, when scientists found decreased expression of hundreds of genes — many of which are key tumor suppressor genes such as BMP3, SFRP2 and GATA4 — in the smoke - exposed cells and a five - or - more-fold increase in the signaling of the KRAS oncogene that is known to be mutated in smoking - related lung cancers.

In the Cell study, Dr. Massagué, with Fellow Manuel Valiente, PhD, and other team members, found that in mouse models of breast and lung cancer — two tumor types that often spread to the brain — many cancer cells that enter the brain are killed by astrocytes.

Potti and his colleagues began by testing chemotherapy drugs on cultured cell lines from human tumors, such as from the lung, breast, or ovary.

Further preclinical work will be needed to use the herpes - loaded stem cells for breast, lung and skin cancer tumors that metastasize to the brain.

A Yale Cancer Center research team conducted a study to determine how those tumor cells manage to grow outside the lungs.

Pembrolizumab, or pembro, an immunotherapy drug that unmasks cancer cells and allows the body's own immune system to help destroy tumors, appears to be safe in treating lung cancers, according to a study by Cancer Treatment Centers of America ® (CTCA) at Western Regional Medical Center (Western) in Goodyear, Arizona.

There is currently a PD - 1 antibody on the market that blocks T cell exhaustion in patients with solid tumors, like lung cancer and melanoma.

«We believe that small subsets of metastatic tumor cells have the ability to adopt the mechanisms used by immune cells to exit the blood vessels into the lungs, the bone marrow, the brain, and other organs.

Compared to a control (left), epalrestat treatment (right) reduces the number of metastatic tumors (arrowheads) in the lungs of mice injected with human basal - like breast cancer cells.

They found out that TiY is capable of distinguishing TICs from non-TICs in various human lung cancer cell lines and patient - derived lung tumors.

The substance vigorously inhibited the growth of cultured tumor cells from colon, lung, and breast cancers, the team reports in the 20 January issue of Angewandte Chemie.

Among patients with non-small cell lung cancer (NSCLC) fueled by ALK gene alterations who were being treated with crizotinib (Xalkori), a decrease in the number of circulating tumor cells (CTCs) harboring increased copies of the ALK gene over the first two months of treatment was associated with increased progression - free survival.

The study, «The nuclear transport receptor Importin - 11 is a tumor suppressor that maintains PTEN protein,» which will be published online February 13 in The Journal of Cell Biology, suggests that the loss of Importin - 11 may destabilize PTEN, leading to the development of lung, prostate, and other cancers.

«FDG PET shows tumor DNA levels in blood are linked to NSCLC aggressiveness: Insights derived from FDG PET could improve treatment selection for patients with advanced non-small cell lung cancer.»

Loss of either GSTO1 or RYR1, the researchers report, decreased the number of cancer stem cells in the primary tumor, blocked metastasis of cancer cells from the primary tumor to the lungs, decreased the duration of chemotherapy required to induce remission and increased the duration of time after chemotherapy was stopped that the mice remained tumor - free.

Italian researches have demonstrated a better way of determining the aggressiveness of tumors in patients with advanced non-small cell lung cancer (NSCLC).

CCL5 attracts tumor cells to the lungs and lymph nodes, and VEGF increases the number of blood vessels and makes them more porous, allowing tumor cells to metastasize and infiltrate the lungs.

Nana - Sinkam and his colleagues examined lung - tumor samples from 81 patients with stage - 1 nonsmall - cell lung cancer and tumor - cell lines.

One of those genes, K - Ras, which was discovered nearly 30 years ago, is mutated in 30 percent of human tumors, including 90 percent of pancreatic cancers, 40 percent of colon cancers, and 20 percent of non-small cell lung cancers.

New research shows that microRNA - 486 is a potent tumor - suppressor molecule in lung cancer, and that the it helps regulate the proliferation and migration of lung - cancer cells, and the induction of programmed cell death, or apoptosis, in those cells.

«High concordance between EGFR mutations from circulating - free tumor DNA and tumor tissue in non-small cell lung cancer.»

Epidermal growth factor receptor (EGFR) mutations found in the circulating free tumor DNA (ctDNA) from the plasma of advanced non-small cell lung cancer (NSCLC) patients correlates well with the EGFR mutations from patient - matched tumor tissue DNA.

To test this idea, the researchers utilized two mouse models of human breast cancer metastasis and found dormant disseminated tumor cells residing upon the membrane microvasculature of lung, bone marrow and brain tissue.

By blocking these in lung endothelial cells, the researchers were able to slow lung tumor growth in mice and also reduce the spread of metastatic tumors.

Given that breast cancer cells traveling through the bloodstream on their way to secondary sites where breast tumors metastasize most often — lung, bone marrow, brain and liver — must first pass through the basement membrane microvasculature, Ghajar and Bissell suspected that the basement membrane could be a major component of the dormant niche in distant organs.

Partnering with the U.S. Food and Drug Administration allowed Doebele and colleagues to access clinical trial data describing initial tumor response, PFS and OS for 305 patients with stage IIIb or IV non-small cell lung cancer on trials of ALK inhibitors and 355 similar patients on trials of immunotherapies directed at PD - 1.

By using molecular genetic tools to reduce the amount of PC in human lung cancer cells, the team observed decreased cell growth, a compromised ability to form colonies in soft agar (a gelatinous material specifically used to grow bacteria and other cells), and a reduced rate of tumor growth in mice.

Other studies have found that nutrients in dark, leafy greens may inhibit the growth of tumor cells in breast, skin, lung and stomach cancers and that green tea may thwart cancer development in colon, liver, breast and prostate cells.

By contrast, 16 out of 17 mice that produced annexin A2 in their cells developed metastatic tumors in the liver, lungs or abdominal cavity.

«We found that many more mice developed tumors when given the cells that we had engineered to have these stem cell characteristics, and they had a much higher incidence of metastasis in the lungs,» Kilian said.

«Communication between lung tumors, bones contributes to tumor progression: Study identifying interaction among tumor cells, bone marrow and immune cells opens new avenue for immunotherapy.»

This soluble factor was found at higher levels in the blood of animals with lung tumors, could increase the activation of osteoblasts and contributed to the maturation of neutrophils in cultured cells.

Examination of gene expression in patients with non-small cell lung cancer (NSCLC) showed the area adjacent to tumors is rich with cancer markers.

«Our findings indicate the existence of long - distance interactions between lung tumors and bones: lung tumors remotely activate osteoblasts, and those bone cells, in turn, shape immunity by supplying tumors with cancer - promoting neutrophils,» says Pittet, who is an associate professor of Radiology at Harvard Medical School.

Both the number and activity of osteoblasts — cells that produce and reshape bone tissue — were increased within the bone marrow of mice with lung tumors compared with cancer - free animals; and reducing the number of osteoblasts in mice not only limited neutrophil infiltration of tumors but also interrupted tumor progression.

In the Dec. 1 issue of Science, the team from the MGH Center for Systems Biology describes a «crosstalk» between lung tumors and bone marrow, which leads to the generation of a type of immune cell that travels to the tumor and promotes its progression.

The cells exhibited many functions associated with tumor progression; their presence within mouse tumors substantially accelerated cancer growth, and in human lung tumors, a SiglecFhigh neutrophil signature was associated with poor patient survival.

A possible explanation may be that, according to prior research findings, tumors of the lung and bowel tend to be colonized by particularly high quantities of immune cells.

Results of an initial study of tumors from patients with lung cancer or head and neck cancer suggest that the widespread acquired resistance to immunotherapy drugs known as checkpoint inhibitors may be due to the elimination of certain genetic mutations needed to enable the immune system to recognize and attack malignant cells.

To investigate why checkpoint inhibitors so often stop working, Velculescu; Valsamo Anagnostou, M.D., Ph.D., instructor of oncology at the Johns Hopkins University School of Medicine; Kellie N. Smith, Ph.D., a cancer immunology research associate at the Johns Hopkins University School of Medicine; and their colleagues at the Bloomberg ~ Kimmel Institute for Cancer Immunotherapy studied tumors of four patients with non-small cell lung cancer and one patient with head and neck cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-CTLA4.

«For example, mouse mammary tumors shared a signaling pathway that is found in human lung cancer and controls how cells reproduce and move from one location to another.»

Among lung cancer patients; suicide SMR was higher in males (SMR = 8.8), Asians (SMR = 13.7), widowed patients (SMR = 11.6), older patients (70 - 75 years; SMR = 12), patients with undifferentiated tumors (SMR 8.6) or small cell lung carcinoma (SCLC) histology (SMR = 11.2), patients presenting with metastatic disease (SMR = 13.9) and in patients who refused to receive surgical treatment (SMR = 13).

Mice injected with breast cancer cells making lots of a long strand of RNA called HOTAIR developed 10 times as many lung tumors as controls (left) did.

Different types of tumors show a preference for specific organs and tissues; circulating breast cancer cells, for example, are likely to take root in bones, lungs, and the brain.

The results from our new study suggest that entinostat may enhance the anti-tumor efficacy of PD - 1 targeted therapy through MDSC targeting, potentially providing an effective combination treatment approach for patients with solid tumors, including lung and renal cell carcinoma.»

«Preclinical results support entinostat's role in targeting the tumor microenvironment: Entinostat inhibits function of myeloid derived suppressor cells resulting in enhanced antitumor effect in murine models of lung and renal cell carcinoma.»

The study's findings, published in the journal Cancer Research, are the first to use these combined agents as an immune stimulator and may have the potential to kill cancerous cells in solid tumors, including some of the most aggressive cancers that form in the lung and pancreas.

In their previous work, the scientists suspected that C / EBPα may act as a tumor suppressant in normal cells, but the mechanism by which its absence promoted lung cancer tumors remained unclear.

In one, a liver and armpit tumor that had developed from spreading melanoma cells shrank, and in the other a lung tumor disappeared.